aXichem (AXIC) Q2 2026 earnings summary

Executive summary

• Net sales for Jan–June 2026 were SEK 7,856 thousand, down from SEK 10,035 thousand year-over-year.

• Operating loss improved to SEK -7,112 thousand from SEK -9,274 thousand year-over-year, mainly due to reduced regulatory costs.

• Significant regulatory milestone achieved with EFSA's positive opinion on phenylcapsaicin as a salmonella-inhibiting additive in chicken feed.

• Commercial launch of aXiphenⓇ ruminant in Brazil, with initial deliveries and new orders secured.

Financial highlights

• Q2 2026 net sales were SEK 4,030 thousand, compared to SEK 6,648 thousand in Q2 2025.

• Profit after tax for Jan–June 2026 was SEK -7,168 thousand, an improvement from SEK -9,289 thousand year-over-year.

• Cash and cash equivalents at June 30, 2026, were SEK 2,873 thousand, down from SEK 6,781 thousand a year earlier.

• Equity ratio increased to 93% from 90% year-over-year.

• Earnings per share for Jan–June 2026 were SEK -0.11, compared to SEK -0.16 year-over-year.

Outlook and guidance

• Anticipates final EU Commission approval for phenylcapsaicin as a feed additive by end of 2026.

• Expects gradually increasing order intake in both animal feed and dietary supplements in coming years.

• Focus remains on commercialization in Brazil, EU, and continued expansion in the US.